Back to News
Dec 10, 2025 4:00 PM

Pfizer's Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) on Wednesday shared detailed results from the Phase 3 HER2CLIMB-05 trial of Tukysa (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction.

• Pfizer shares are showing limited movement. Where is PFE stock headed?

The trial included patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

The primary endpoint analysis showed a 35.9% reduction in ...